Ophthalmology Science Names FQHCs as 'Ideal Locations' for Autonomous AI Diabetic Retinopathy Screening — Real-World Adoption Playbook

Ophthalmology Science (Sept 2025, broadly cited in April 2026 Modern Retina + Ophthalmology Times coverage) published the first peer-reviewed multi-system adoption study of autonomous AI DR screening: LumineticsCore + EyeArt + AEYE-DS. Real-world gradability 49-75%, sensitivity 87-100%, specificity 60-91%. The paper explicitly names FQHCs as 'ideal locations' for autonomous AI DR screening and provides workflow, staffing, and billing implementation framework FQHCs can replicate. Reinforces CPT 92229 reimbursement path (Medicare 2025 = $43.67/screening — autonomous AI pays MORE than human interpretation). Combined with the CalMatters $47/16% kids vision crisis story, this is the strategic moment for FQHCs to scale optometry + AI-screening service lines. Topcon NW400 fundus camera ($15-25K, refurbished from $3,278) pays for itself within months at typical FQHC volume.